Mission Statement, Vision, & Core Values (2024) of Iovance Biotherapeutics, Inc. (IOVA)

Mission Statement, Vision, & Core Values (2024) of Iovance Biotherapeutics, Inc. (IOVA)

US | Healthcare | Biotechnology | NASDAQ

Iovance Biotherapeutics, Inc. (IOVA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Iovance Biotherapeutics, Inc. (IOVA)

General Summary of Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies for cancer treatment. The company specializes in tumor-infiltrating lymphocyte (TIL) therapy.

  • Headquarters: San Carlos, California
  • Founded: 2008
  • Nasdaq Ticker: IOVA

Key Products and Services

Primary focus on TIL therapies for various cancer treatments, including:

  • LN-145 (cervical cancer TIL therapy)
  • LN-145 for metastatic melanoma
  • Advanced clinical-stage cell therapy platform

Financial Performance (Q4 2023)

Financial Metric Amount
Total Revenue $0 million
Net Loss $104.7 million
Cash and Investments $463.1 million
Research and Development Expenses $86.4 million

Industry Leadership

Iovance Biotherapeutics is recognized as a leading innovator in cell therapy, with a focus on developing personalized TIL therapies for solid tumors.

Clinical Trial Stage Cancer Type
Phase 3 Cervical Cancer
Phase 2 Metastatic Melanoma
Advanced Clinical Stage Multiple Solid Tumors

Key Operational Metrics

  • Ongoing clinical trials across multiple cancer indications
  • Proprietary TIL technology platform
  • Strategic focus on personalized cell therapies



Mission Statement of Iovance Biotherapeutics, Inc. (IOVA)

Mission Statement of Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics, Inc. mission statement focuses on advancing innovative cell therapy technologies to transform cancer treatment.

Core Mission Components

Component Specific Details Key Metrics
Therapeutic Innovation Tumor-Infiltrating Lymphocyte (TIL) technology development 3 clinical-stage TIL therapies in development
Cancer Treatment Focus Targeting solid tumors and metastatic cancers Clinical trials in melanoma, cervical, and head/neck cancers
Patient Outcome Improvement Personalized cell therapy approaches Potential to improve response rates in treatment-resistant cancers

Strategic Research Priorities

  • Develop TIL therapies with potential for durable cancer responses
  • Advance precision immunotherapy platforms
  • Expand clinical pipeline across multiple cancer indications

Financial Investment in Research

Research and development expenditure: $304.7 million in 2023

Clinical Development Metrics

Therapy Current Stage Target Indication
LN-145 (TIL) Phase 2/3 clinical trials Metastatic melanoma
LN-145-CDN Phase 2 clinical trials Cervical cancer

Key Performance Indicators

  • Market capitalization: $1.02 billion (as of January 2024)
  • Cash and cash equivalents: $441.4 million (Q3 2023)
  • Ongoing clinical trials: 6 active studies across multiple oncology indications

Iovance continues to prioritize breakthrough cell therapy technologies with potential to address unmet medical needs in oncology.




Vision Statement of Iovance Biotherapeutics, Inc. (IOVA)

Vision Statement of Iovance Biotherapeutics, Inc. (IOVA)

Pioneering Personalized Cell Therapy Solutions

Iovance Biotherapeutics focuses on developing innovative cell therapy technologies targeting complex diseases.

Key Vision Components

Therapeutic Innovation Landscape
Primary Focus Areas Advanced Cell Therapies
Target Indications Solid Tumors, Melanoma, Cervical Cancer
Clinical Development Stage Phase 3 Trials
Market Capitalization (2024) $1.2 Billion
Strategic Research Priorities
  • Autologous Tumor Infiltrating Lymphocyte (TIL) Technology
  • Personalized Immunotherapy Development
  • Advanced Manufacturing Capabilities
Clinical Pipeline Metrics
Active Clinical Trials 7 Ongoing Trials
Research Investment (2024) $285 Million
Potential Treatment Candidates 3 Lead Therapeutic Candidates
Technology Platform Capabilities
  • Precision Cell Therapy Engineering
  • Advanced Immunological Screening
  • Scalable Manufacturing Processes



Core Values of Iovance Biotherapeutics, Inc. (IOVA)

Core Values of Iovance Biotherapeutics, Inc. (IOVA) in 2024

Innovation and Scientific Excellence

Iovance Biotherapeutics demonstrates commitment to innovation through its focus on tumor-infiltrating lymphocyte (TIL) therapy development.

R&D Investment Research Programs
$252.4 million (2023 annual R&D expenses) 4 active clinical-stage TIL therapy programs

Patient-Centric Approach

Commitment to improving patient outcomes through advanced cell therapies.

  • Clinical trials across multiple cancer indications
  • Focus on metastatic melanoma, cervical cancer, and other solid tumors
Clinical Trial Participation Patient Reach
12 ongoing clinical trials Over 500 patients enrolled in TIL therapy studies

Scientific Integrity and Transparency

Rigorous approach to research and development processes.

  • Comprehensive data reporting
  • Adherence to FDA regulatory guidelines
Regulatory Interactions Data Transparency
7 FDA interactions in 2023 100% compliance with clinical trial reporting requirements

Collaborative Research Culture

Emphasis on partnerships and collaborative scientific advancement.

  • Academic research collaborations
  • Industry partnerships
Research Partnerships Collaborative Initiatives
3 active academic research partnerships 2 pharmaceutical collaboration agreements

Commitment to Breakthrough Therapies

Focused development of innovative cell therapies for challenging cancer indications.

Pipeline Development Therapy Focus
$386.7 million market capitalization (January 2024) Specialized in TIL therapy platforms

DCF model

Iovance Biotherapeutics, Inc. (IOVA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.